“…Moreover, 15 (11.1%) studies included persons with specific conditions such as Alzheimer disease [ 33 - 35 ], Parkinson disease [ 36 ], frontotemporal lobar degeneration [ 37 ], severe cognitive impairments [ 38 ], ovarian cancer [ 39 ], gynecological cancer [ 40 ], patients with cancer actively treated with systemic therapy [ 41 ], pre-existing depression [ 42 ], chronic conditions [ 43 ], long-term respiratory conditions [ 44 ], migraine [ 45 ], epilepsy [ 46 ], and visual impairments [ 47 ]. A total of 29 (21.5%) studies were conducted in North America [ 40 , 42 , 43 , 48 - 73 ], 14 (10.3%) in China [ 46 , 74 - 86 ], 61 (45.1%) in Europe [ 33 - 38 , 41 , 44 , 87 - 139 ], 3 (2.2%) in Japan [ 140 - 142 ], 4 (3.0%) in Israel [ 143 - 146 ], 4 (3.0%) in Brazil [ 147 - 150 ], 4 (3.0%) in Australia [ 151 - 154 ], 2 (1.5%) in India [ 155 , 156 ], 1 (0.7%) in Malaysia [ 157 ], 2 (1.5%) in Kuwait [ 45 , 158 ], 1 (0.7%) in Saudi Arabia [ 159 ], 3 (2.2%) in Argentina [ 160 - 162 ], 1 (0.7%) in Cameroon [ 163 ], 1 (0.7%) in Russia [ 164 ], 1 (0.7%) in Ghana [ 47 ], 1 (0.7% in Cyprus [ 165 ], and 3 (2.2%) in multiple countries [ 39 , 166 , 167 ].…”